Clinical Trial: Study of Morphine in Postoperative Infants to Allow Normal Ventilation

This study is no longer recruiting patients.

Sponsors and Collaborators: FDA Office of Orphan Products Development
Children's Hospital and Medical Center - Seattle
Information provided by: FDA Office of Orphan Products Development

Purpose

OBJECTIVES: I. Compare nonmechanically ventilated infants who receive morphine postoperatively as intermittent intravenous bolus doses or as a continuous intravenous infusion targeted to reach a steady-state concentration. II. Assess ventilation (blood gases, continuous oximetry, and CO2 response curves) and analgesia (infant pain score) between the two treatment groups of infants. III. Compare ventilation parameters (blood gases, CO2 response curves, and time to wean from assisted mechanical ventilation) in cyanotic and acyanotic infants after thoracotomies.

Condition Treatment or Intervention
Infant, Newborn, Diseases
Pain
 Drug: morphine

MedlinePlus related topics:  Infant and Toddler Health;   Pain

Study Type: Interventional
Study Design: Educational/Counseling/Training, Randomized

Further Study Details: 

Expected Total Enrollment:  100

Study start: August 1994

PROTOCOL OUTLINE: This is a two part study. Infants are stratified by age (1-30 days vs 31-180 days vs 181-365 days) and by type of surgery. Infants are randomly assigned to one of two treatment arms. In part I, following major thoracic, abdominal, or cardiac surgery, infants are randomized to receive either continuous IV morphine infusions (arm I) or to receive morphine by single IV bolus doses every 2-3 hours (arm II). In part II, cyanotic and acyanotic infants following thoracotomy receive morphine by 2 loading doses over 15 minutes and then by continuous IV infusion. Patients are followed for at least 2 days.

Eligibility

Ages Eligible for Study:  up to  1 Year,  Genders Eligible for Study:  Both

Criteria

PROTOCOL ENTRY CRITERIA: --Disease Characteristics--

  • Infants scheduled for surgery with postoperative inpatient care
  • Must be born after 35 weeks or more gestational age
  • No prenatal opiate exposure

Part I patients:

  • Less than 12 months of age undergoing surgeries involving major thoracic, abdominal, or cardiac procedures
  • No pneumonectomy, tracheal or bronchial stenosis reconstruction, diaphragmatic hernia repair, or surgeries resulting in high intraabdominal pressure (closure of large gastroschisis or omphalocele defects)
  • No hepatic or renal transplantation

Part II patients:

  • Less than 3 months of age undergoing surgeries using a thoracotomy approach
  • Cyanotic congenital heart disease having palliative systemic to pulmonary artery shunts created OR Thoracotomy for repair of acyanotic lesions (e.g., repairs of coarctation of the aorta, tracheoesophageal fistula repair, PDA ligation)

--Patient Characteristics--

  • Age: Part I: Less than 12 months Part II: Less than 3 months
  • Hepatic: Normal hepatic function tests
  • Renal: Normal renal function tests
  • Pulmonary: No pulmonary disease causing baseline hypercarbia
  • No pulmonary hypertension contraindicating use of 5% CO2 in rebreathing studies

Other:

  • No allergy to morphine
  • No severe developmental delay that precludes analgesia scoring

Location Information

Study chairs or principal investigators

Anne M. Lynn,  Study Chair,  Children's Hospital and Medical Center - Seattle   

More Information

Publications

Lynn A, Nespeca MK, Bratton SL, Strauss SG, Shen DD. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg. 1998 May;86(5):958-63.

Study ID Numbers:  199/13359; CHMC-S-FDR001015; CHMC-S-IRB-022-9801; CHMC-S-IRB-148-9706
Record last reviewed:  May 1999
Last Updated:  October 13, 2004
Record first received:  February 24, 2000
ClinicalTrials.gov Identifier:  NCT00004696
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources